Given the present findings that vitamin D inhibit IL-22 expression in malignant T cells, we hypothesize that vitamin D supplementation could have a beneficial effect as adjuvant therapy inhibiting ectopic IL-22 expression and skin inflammation in CTCL. This evidence concerns the gene IL22 and primary cutaneous T-cell non-Hodgkin lymphoma.